SUNTEC-GROUP
9.12.2021 06:26:14 CET | Business Wire | Pressemeddelelse
SunTec Business Solutions, verdens førende prisfastsættelses- og faktureringsvirksomhed, meddelte i dag, at virksomheden er blevet valgt af Nordens førende erhvervsbank, SEB, til en koncernomspændende global udrulning og til at automatisere deres næste generation af tilbud-til-fakturering-program. SunTecs pakke med løsninger vil digitalisere bankens salgsproces, fra aftalehåndtering og prisfastsættelse til fakturering.
SEB valgte SunTec som teknologipartner til at hjælpe med at opfylde deres vigtigste strategiske initiativer for at blive førende inden for kundeoplevelser, skabe robusthed og fleksibilitet i banken og øge aktiviteterne for store erhvervs- og finansinstitutioner samt SMV'er.
Olle Durelius, Co-Head Transaction Services hos SEB, fortæller, "Vores ambition er at opgradere vores eksisterende processer, og vi er meget glade for at have indgået et partnerskab med SunTec og starter denne rejse for at forbedre og fremme digitalisering og automatisering. Vi var på udkig efter en løsningsudbyder, der kunne understøtte transformationen af vores aktiviteter. I SunTec fandt vi en ligesindet partner, der kunne hjælpe os med at digitalisere vores salgsproces, sikre hurtigere time-to-market, stoppe indtægtslækager, reducere manuel indgriben og sikre, at vi fakturerer klienterne i overensstemmelse med deres forventninger. Med SunTecs pakke med løsninger og platformen Xelerate vil vi understøtte vores aktiviteter inden for likviditetsstyring samt globale depotydelser og "sub-custody" til en start."
Nanda Kumar, grundlægger og CEO hos SunTec, udtaler, "Vi er meget glade for at have indgået et partnerskab med SEB for at styrke deres position som rådgiver til erhvervsklienter, forbedre driftsmæssig fortræffelighed og sikre digital distribution af deres tilbud. Vores robuste pakke med løsninger udrullet på vores Xelerate-platform vil tilbyde en teknologisk infrastruktur, der er API-venlig, modulopbygget af natur, og som automatiserer deres tilbud til fakturering-livscyklus. Denne aftale er en milepæl for os i Norden og viser, at banker i stigende grad skal gå mod en arkitektur i tre lag og udnytte et intelligent midterlag for at sikre agilitet og kundecentrering."
Om SunTec
SunTec er verdens førende prisfastsættelses- og faktureringsvirksomhed, der skaber værdi for virksomheder via cloudbaserede produkter. Mere end 130 klienter i over 45 lande stoler på, at SunTec kan levere meget personligt tilpassede produkter, tilbud, prisfastsættelse, loyalitetsprogrammer og fakturering for mere end 400 millioner slutkunder. SunTecs produkter er baseret på vores cloud-native og cloud-agnostiske, API first, mikrotjenestebaserede proprietære platform, Xelerate, og leveres på stedet, på privat cloud og som SaaS. SunTec har globale aktiviteter, der omfatter USA, Storbritannien, Tyskland, Forenede Arabiske Emirater, Singapore, Canada, Australien og Indien. Besøg www.suntecgroup.com for at få flere oplysninger, eller send en e-mail til os på marketing@suntecgroup.com .
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211208006173/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
